

# Koonal Shah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4754625/publications.pdf>

Version: 2024-02-01

58  
papers

2,468  
citations

331670

21  
h-index

206112

48  
g-index

60  
all docs

60  
docs citations

60  
times ranked

4275  
citing authors

#	ARTICLE	IF	CITATIONS
1	Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology. <i>European Journal of Health Economics</i> , 2023, 24, 293-305.	2.8	7
2	Exploration of the Reasons Why Health State Valuation Differs for Children Compared With Adults: A Mixed Methods Approach. <i>Value in Health</i> , 2022, 25, 1185-1195.	0.3	16
3	Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experimentâ€™Based Valuation Studies Affect Health Preferences?. <i>Value in Health</i> , 2022, 25, 1196-1204.	0.3	10
4	Criteria for developing, assessing and selecting candidate EQ-5D bolt-ons. <i>Quality of Life Research</i> , 2022, 31, 3041-3048.	3.1	5
5	Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?. <i>Medical Decision Making</i> , 2021, 41, 584-596.	2.4	30
6	Impact of Including Carer Information in Time Trade-Off Tasks: Results from a Pilot Study. <i>Pharmacoeconomics - Open</i> , 2021, 5, 665-675.	1.8	0
7	Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. <i>European Journal of Health Economics</i> , 2021, 22, 1301-1309.	2.8	3
8	EQ-5D-5L Health-State Values for the Mexican Population. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 905-914.	2.1	11
9	Economic evaluation of meningococcal vaccines: considerations for the future. <i>European Journal of Health Economics</i> , 2020, 21, 297-309.	2.8	25
10	HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. <i>European Journal of Health Economics</i> , 2020, 21, 1421-1437.	2.8	38
11	The EQ-5D-5L Value Set for England: Response to the â€™Quality Assuranceâ€™. <i>Value in Health</i> , 2020, 23, 649-655.	0.3	16
12	An exploration of methods for obtaining 0â€™=â€™dead anchors for latent scale EQ-5D-Y values. <i>European Journal of Health Economics</i> , 2020, 21, 1091-1103.	2.8	36
13	Using EQ-5D Data to Measure Hospital Performance: Are General Population Values Distorting Patientsâ€™ Choices?. <i>Medical Decision Making</i> , 2020, 40, 511-521.	2.4	5
14	Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5L valuation study in Ireland. <i>Health Policy</i> , 2020, 124, 639-646.	3.0	4
15	International Valuation Protocol for the EQ-5D-Y-3L. <i>Pharmacoeconomics</i> , 2020, 38, 653-663.	3.3	84
16	A new method for valuing health: directly eliciting personal utility functions. <i>European Journal of Health Economics</i> , 2019, 20, 257-270.	2.8	26
17	Cultural Values: Can They Explain Differences in Health Utilities between Countries?. <i>Medical Decision Making</i> , 2019, 39, 605-616.	2.4	42
18	The value of international volunteers experience to the NHS. <i>Globalization and Health</i> , 2019, 15, 31.	4.9	8

#	ARTICLE	IF	CITATIONS
19	A note on the relationship between age and health-related quality of life assessment. <i>Quality of Life Research</i> , 2019, 28, 1201-1205.	3.1	6
20	Valuing health at the end of life: A review of stated preference studies in the social sciences literature. <i>Social Science and Medicine</i> , 2018, 204, 39-50.	3.8	23
21	Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. <i>Pharmacoeconomics</i> , 2018, 36, 699-713.	3.3	74
22	New methods for modelling EQ-5D-5L value sets: An application to English data. <i>Health Economics (United Kingdom)</i> , 2018, 27, 23-38.	1.7	61
23	Evaluation of Split Version and Feedback Module on the Improvement of Time Trade-Off Data. <i>Value in Health</i> , 2018, 21, 732-741.	0.3	11
24	Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research. <i>Patient</i> , 2018, 11, 253-270.	2.7	21
25	Valuing EQ-5D-5L health states "in context" using a discrete choice experiment. <i>European Journal of Health Economics</i> , 2018, 19, 595-605.	2.8	8
26	Valuing health-related quality of life: An EQ-5D-5L value set for England. <i>Health Economics (United Kingdom)</i> , 2018, 27, 101-117.	1.7	863
27	How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?. <i>Medical Decision Making</i> , 2018, 38, 306-318.	2.4	9
28	Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. <i>Value in Health</i> , 2018, 21, 1291-1298.	0.3	70
29	Euthanasia, religiosity and the valuation of health states: results from an Irish EQ5D5L valuation study and their implications for anchor values. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 152.	2.4	8
30	Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. <i>Pharmacoeconomics</i> , 2018, 36, 1345-1353.	3.3	67
31	Views of the UK General Public on Important Aspects of Health Not Captured by EQ-5D. <i>Patient</i> , 2017, 10, 701-709.	2.7	21
32	Is willingness to pay higher for cancer prevention and treatment?. <i>Journal of Cancer Policy</i> , 2017, 11, 60-64.	1.4	12
33	The effect of religion on the perception of health states among adults in the United Arab Emirates: a qualitative study. <i>BMJ Open</i> , 2017, 7, e016969.	1.9	19
34	Does Society Place Special Value on End of Life Treatments?. , 2016, , 155-166.		3
35	EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes. <i>Pharmacoeconomics</i> , 2016, 34, 993-1004.	3.3	170
36	An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies. <i>Value in Health</i> , 2016, 19, 53-59.	0.3	14

#	ARTICLE	IF	CITATIONS
37	Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?. Value in Health, 2016, 19, 210-217.	0.3	21
38	IS THE LINK BETWEEN HEALTH AND WEALTH CONSIDERED IN DECISION MAKING? RESULTS FROM A QUALITATIVE STUDY. International Journal of Technology Assessment in Health Care, 2015, 31, 449-456.	0.5	4
39	PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH. International Journal of Technology Assessment in Health Care, 2015, 31, 90-98.	0.5	16
40	Government and charity funding of cancer research: public preferences and choices. Health Research Policy and Systems, 2015, 13, 38.	2.8	5
41	An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate Health State Values in the United Arab Emirates. Value in Health Regional Issues, 2015, 7, 34-41.	1.2	20
42	Valuing health at the end of life: A stated preference discrete choice experiment. Social Science and Medicine, 2015, 124, 48-56.	3.8	69
43	Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 2014, 52, 935-943.	2.4	38
44	Valuing health at the end of life: an empirical study of public preferences. European Journal of Health Economics, 2014, 15, 389-399.	2.8	49
45	A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO. Health Economics (United) Tj ETQq1, 1, 0.784314 rgBT 1.7 51	1.7	51
46	One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands. European Journal of Health Economics, 2013, 14, 65-73.	2.8	23
47	A REVIEW OF HEALTH TECHNOLOGY APPRAISALS: CASE STUDIES IN ONCOLOGY. International Journal of Technology Assessment in Health Care, 2013, 29, 101-109.	0.5	14
48	NICE's social value judgements about equity in health and health care. Health Economics, Policy and Law, 2013, 8, 145-165.	1.8	38
49	Using patient-reported outcome measures to estimate cost-effectiveness of hip replacements in English hospitals. Journal of the Royal Society of Medicine, 2013, 106, 323-331.	2.0	31
50	Is the aim of the English health care system to maximize QALYs?. Journal of Health Services Research and Policy, 2012, 17, 157-163.	1.7	25
51	Using QALYs in Cancer. Pharmacoeconomics, 2011, 29, 673-685.	3.3	74
52	Severity of illness and priority setting in healthcare: A review of the literature. Health Policy, 2009, 93, 77-84.	3.0	145
53	Valuing Health at the End of Life: A Stated Preference Discrete Choice Experiment. SSRN Electronic Journal, 0, , .	0.4	0
54	An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate EQ-5D-5L Values in the United Arab Emirates. SSRN Electronic Journal, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
55	Understanding Social Preferences Regarding the Prioritisation of Treatments Addressing Unmet Need and Severity. SSRN Electronic Journal, 0, , .	0.4	3
56	Valuing Health at the End of Life: An Exploratory Preference Elicitation Study. SSRN Electronic Journal, 0, , .	0.4	4
57	Understanding Social Preferences Regarding the Prioritisation of Treatments Addressing Unmet Need and Severity. SSRN Electronic Journal, 0, , .	0.4	2
58	Is the Link between Health and Wealth Considered in Decision Making? Results from a Qualitative Study. SSRN Electronic Journal, 0, , .	0.4	0